NanoGhost

Naturally Targeted Drug Platform

Health Tech & Life Sciences
Active
Seed Netanya, Israel Founded 2019
Last updated 2026-06-18
Total raised
$9.0M
Last: 2023-06
Stage
Seed
Founded
2019
Headcount
12
HQ
Netanya, Israel
Sector
Health Tech & Life Sciences

About

NanoGhost is a drug-delivery technology that uses adult stem cells to transport medicine directly to the tumor site. The technology has already proven successful in treating pancreatic, lung, breast, prostate, and brain cancer in mice. The platform is based on nano-vesicles, termed Nano-Ghosts (NGs), which are technologically reconstructed from the cell membranes of naturally targeted allogeneic mesenchymal stem cells (MSCs), after removing their cytoplasm and nuclei. The NGs' safety and targeting capabilities rely on their retention of the surface-associated mechanisms that govern MSCs' well-documented allogeneic tolerability and targeting of multiple inflamed and malignant tissues. The NanoGhost technology was developed by Professor Marcel Machluf, the faculty dean of Biotechnology & Food Engineering at the Technion-Israel Institute of Technology. Professor Machluf developed the technology in her lab at the Technion and set up a start-up as a spin-off from the university to commercialize the technology. Israel's Ministry of Science and Technology named NanoGhost as one of Israel's 60 most impactful developments. The NanoGhost technology has been patented in the United States and Europe, with additional patents pending in India and China.

Funding history · 2 rounds · $9.0M total

2023-06
2019-12
$5.0M

Q&A

What is NanoGhost's core technology?
NanoGhost utilizes a drug-delivery technology based on nano-vesicles, called Nano-Ghosts (NGs), which are reconstructed from the cell membranes of naturally targeted allogeneic mesenchymal stem cells (MSCs). These NGs are designed to transport medicine directly to tumor sites.
When was NanoGhost founded?
NanoGhost was founded in August 2019.
How many employees does NanoGhost currently have?
NanoGhost has 11-50 employees.
Who developed the NanoGhost technology?
The NanoGhost technology was developed by Professor Marcel Machluf, the faculty dean of Biotechnology & Food Engineering at the Technion-Israel Institute of Technology. She also founded the company as a spin-off from the university.
Has NanoGhost secured any funding recently?
Yes, NanoGhost raised $4,000,000 in June 2023 from New Gate Capital.
What is NanoGhost's total funding to date?
NanoGhost has raised a total of $9,000,000 across its funding rounds.
In which countries is NanoGhost's technology patented?
The NanoGhost technology has been patented in the United States and Europe, with additional patents pending in India and China.
What is the primary sector of NanoGhost?
NanoGhost's primary sector is Health Tech & Life Sciences.
Who is the CEO of NanoGhost?
Yonatan Malca is the CEO of NanoGhost.

Team · 1

Founder · Founder & inventor

Sectors & technology

Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical Biotechnology
Technologies
Materials & SubstancesBiologicalsCells
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticals
Business model
B2B

Highlights

1 PatentsVerified

Tags

targeted-cancer-therapycancertargeted-therapystem-cellsdrug-deliverynanotechnologyimmunotherapytreatmentspharmaceuticalsbiotechnologygenetics
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)

External links

Websitenano-ghost.com/
LinkedInlinkedin.com/company/80018810

Identifiers & details

Former namesNano Ghosts
Founded2019-8
Employees (exact)12

Radar intelligence

Web history (Wayback)

Domainnano-ghost.com

Certificate / subdomain footprint

Subdomains1